Pharma Investment Firms

RaiseHunt lists 1,040 Pharma investment firms.

1,024 of the 1,040 firms list at least one portfolio company, 7,424 known investments between them.

3,650 people working at them have a profile here, each with their role at the firm and whether an email address is on file.

The largest concentrations are in New York, Boston and London.

Most list Seed and Series A among their stages.

Every firm page shows whether an email address is on file, and the named contacts at that firm. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.

Yes. The directory and every firm page are free to read. Matching your own startup against them requires an account.

No. A focus area is a signal of interest, not a restriction. Firms usually list several, and the useful question is whether the existing portfolio looks like the kind of company you are building.

Usually by a group rather than by the person you first spoke to. One partner sponsors the deal internally and takes it to the rest, which is why the process runs longer than an angel conversation and why a single enthusiastic meeting is not yet a commitment.

Less than it used to. Plenty of firms back companies outside their own city, and remote first meetings are normal. Being nearby helps with introductions and later conversations, but it is rarely the thing that decides an investment.

Usually the list was too short or too loosely matched, not that the company is unfundable. Widen it, tighten who you are writing to, and rewrite the first two lines of the message. Those lines decide whether anything below them gets read.

An angel invests their own money and can decide alone, which usually makes the process shorter. A firm invests money it raised from other people, so it answers to those backers and normally runs a longer diligence process before it commits. Founders often raise from angels first and bring in a firm once there is more to show.

A named partner or principal, not a general company address. Investment decisions sit with individual people, and a message that lands in a shared inbox usually stops there. Each fund page here lists the people we hold a profile for, with their role at the firm.